Vor Biopharma Inc.
VOR
$0.634
$0.0142.26%
| Weiss Ratings | VOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | VOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | VOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.72 | |||
| Price History | VOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -28.31% | |||
| 30-Day Total Return | -55.04% | |||
| 60-Day Total Return | -51.97% | |||
| 90-Day Total Return | -17.15% | |||
| Year to Date Total Return | -43.39% | |||
| 1-Year Total Return | -69.67% | |||
| 2-Year Total Return | -87.88% | |||
| 3-Year Total Return | -90.16% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -72.20% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | VOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.23 | |||
| 52-Week Low Price | $0.62 | |||
| 52-Week Low Price (Date) | Apr 01, 2025 | |||
| 52-Week High Price (Date) | Apr 04, 2024 | |||
| Valuation | VOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 77.41M | |||
| Enterprise Value | 17.31M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.70 | |||
| Earnings Per Share Growth | -3.01% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 0.29 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.63 | |||
| Enterprise Value/EBITDA (TTM) | -0.15 | |||
| Enterprise Value/EBIT | -0.14 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | VOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 70.02M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | VOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 655 6580 | |||
| Address | 100 Cambridgepark Drive Cambridge, MA 02140 | |||
| Website | www.vorbio.com | |||
| Country | United States | |||
| Year Founded | 2015 | |||
| Profitability | VOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | VOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -44.42% | |||
| Return on Equity | -- | |||
| Income Statement | VOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -117.66M | |||
| EBIT (TTM) | -121.19M | |||
| Net Income (TTM) | -116.91M | |||
| Net Income Avl. to Common (TTM) | -116.91M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -16.95% | |||
| EPS Diluted (TTM) | -1.70 | |||
| EPS Diluted Growth (Q YOY) | -13.30% | |||
| Balance Sheet | VOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 91.93M | |||
| Cash Per Share (Q) | $1.31 | |||
| Total Current Assets (Q) | 96.51M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 96.66M | |||
| Current Ratio (Q) | 5.185 | |||
| Book Value Per Share (Q) | $2.16 | |||
| Total Assets (Q) | 142.89M | |||
| Total Current Liabilities (Q) | 18.61M | |||
| Total Debt (Q) | 31.83M | |||
| Total Liabilities (Q) | 46.23M | |||
| Total Common Equity (Q) | 96.66M | |||
| Cash Flow | VOR - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 96.86M | |||
| Cash from Financing (TTM) | 53.39M | |||
| Net Change in Cash (TTM) | 50.59M | |||
| Levered Free Cash Flow (TTM) | -83.69M | |||
| Cash from Operations (TTM) | -99.66M | |||
